The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms, and the gravity of unmet needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Immuno-oncology in Pharmaceuticals: Genetic engineered chimeric antibodies.
According to GlobalData’s Technology Foresights, which uses over 756,000 patents to analyse innovation intensity for the pharmaceutical industry, there are 110 innovation areas that will shape the future of the industry.
Genetically engineered chimeric antibodies is a key innovation area in immuno-oncology
Chimeric antibodies are molecules created by fusing the variable domain of an antibody from one host species, such as mouse, rabbit, and llama, with the constant domain of an antibody from another species, such as humans. In 1997, the anti-CD20 chimeric antibody rituximab became the first FDA-approved immunotherapy for cancer.
GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 340+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of genetically engineered chimeric antibodies.
Key players in the genetically engineered chimeric antibodies space – a disruptive innovation in the pharmaceutical industry
‘Application diversity’ measures the number of different applications identified for each relevant patent and broadly splits companies into either ‘niche’ or ‘diversified’ innovators.
‘Geographic reach’ refers to the number of different countries each relevant patent is registered in and reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.
Patent volumes related to genetically engineered chimeric antibodies space
|Company||Total patents (2010 - 2021)||Premium intelligence on the world's largest companies|
|Regeneron Pharmaceuticals||957||Unlock company profile|
|Bristol-Myers Squibb||607||Unlock company profile|
|Cellectis||468||Unlock company profile|
|Memorial Sloan Kettering Cancer Center||409||Unlock company profile|
|Sanofi||390||Unlock company profile|
|Gilead Sciences||325||Unlock company profile|
|F. Hoffmann-La Roche||325||Unlock company profile|
|Autolus||322||Unlock company profile|
|Eureka Therapeutics||288||Unlock company profile|
|City of Hope||283||Unlock company profile|
|Amgen||272||Unlock company profile|
|Merck & Co||262||Unlock company profile|
|Fred Hutchinson Cancer Research Center||227||Unlock company profile|
|Miltenyi Biotec||211||Unlock company profile|
|bluebird bio||198||Unlock company profile|
|Seattle Children's Hospital||174||Unlock company profile|
|Pfizer||172||Unlock company profile|
|CARsgen Therapeutics||159||Unlock company profile|
|Xencor||153||Unlock company profile|
|ImmunityBio||149||Unlock company profile|
|Apogenix||129||Unlock company profile|
|Philogen||128||Unlock company profile|
|BioNTech||122||Unlock company profile|
|CRISPR Therapeutics||121||Unlock company profile|
|Molecular Templates||112||Unlock company profile|
|Nanjing Legend Biotech||102||Unlock company profile|
|Allogene Therapeutics||94||Unlock company profile|
|United States Of America||94||Unlock company profile|
|TCR2 Therapeutics||92||Unlock company profile|
|Innovative Cellular Therapeutics||91||Unlock company profile|
|Aleta Biotherapeutics||87||Unlock company profile|
|PsiOxus Therapeutics||86||Unlock company profile|
|Johnson & Johnson||85||Unlock company profile|
|Massachusetts General Hospital||84||Unlock company profile|
|PT Soho Global Health Tbk||82||Unlock company profile|
|Ecole Polytechnique Federale de Lausanne||80||Unlock company profile|
|Immunocore Holdings||78||Unlock company profile|
|Compugen||74||Unlock company profile|
|AstraZeneca||74||Unlock company profile|
|Precigen||66||Unlock company profile|
|Sangamo Therapeutics||66||Unlock company profile|
|PPF Group||65||Unlock company profile|
|E. Merck||65||Unlock company profile|
|Immatics||65||Unlock company profile|
|Dragonfly Therapeutics||64||Unlock company profile|
|Biogen||62||Unlock company profile|
|Precision Biosciences||61||Unlock company profile|
|C. H. Boehringer Sohn||61||Unlock company profile|
|Poseida Therapeutics||56||Unlock company profile|
|Bayer||55||Unlock company profile|
Source: GlobalData Patent Analytics
Regeneron Pharmaceuticals is the leading patent filer for genetically engineered chimeric antibodies. Its products are focused on helping patients suffering from cancer, allergic and inflammatory diseases, eye diseases, metabolic and cardiovascular diseases, infectious diseases, neuromuscular diseases, haematologic conditions, pain, and rare diseases. The company develops products using its Trap and VelociSuite technology platforms, which include VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, and other related technologies.
In terms of application diversity, the Centre for Digestive Diseases ileads the pack, followed by Susavion Biosciences and the Children's Hospital Los Angeles. By means of geographic reach, I'rom Group holds the top position, while Instil Bio and Les Laboratoires Servier are in second and third positions, respectively.
To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Immuno-Oncology – Thematic Research.